Determinants of Change in Prostate-Specific Antigen Over Time and Its Association With Recurrence After External Beam Radiation Therapy for Prostate Cancer in Five Large Cohorts

International Journal of Radiation Oncology Biology Physics

Volumn 72, Issue 3, 2008, Pages 782-791

  Proust Lima, Cécile ^a   Taylor, Jeremy M G ^a   Williams, Scott G ^b   Ankerst, Donna P ^c   Liu, Ning ^a   Kestin, Larry L ^d   Bae, Kyounghwa ^e   Sandler, Howard M ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d WILLIAM BEAUMONT HOSPITAL   (United States)

^e RADIATION THERAPY ONCOLOGY GROUP   (United States)

Author keywords

Prognostic calculator; Prostate cancer; Prostate specific antigen; PSA velocity; Radiation therapy

Indexed keywords

ANTIGENS; DECISION MAKING; RADIATION; RADIOTHERAPY; RISK ANALYSIS; RISK ASSESSMENT; RISK MANAGEMENT; RISK PERCEPTION; STANDARDS;

AFTER-TREATMENT; CLINICAL FAILURES; COX MODEL; CURRENT SLOPE; DISEASE PROGRESSIONS; EXTERNAL BEAM RADIATION; EXTERNAL BEAM RADIATION THERAPY; GLEASON SCORE; LINEAR MIXED MODEL; PRE TREATMENTS; PREDICTIVE VALUES; PROGNOSTIC CALCULATOR; PROGNOSTIC FACTORS; PROSTATE CANCER; PROSTATE-SPECIFIC ANTIGEN; PSA VELOCITY; RADIATION THERAPY; RISK FACTORS; STATISTICAL MODELLING; TEMPORAL CHANGES;

PEELING;

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RADIATION DOSE; TREATMENT FAILURE;

ADENOCARCINOMA; AGED; COHORT STUDIES; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; RECURRENCE; RISK FACTORS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 52949137903     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.01.056     Document Type: Article

References (31)

1. Roach III M., Weinberg V., Sandler H., et al. Staging for prostate cancer: Time to incorporate pretreatment prostate-specific antigen and Gleason score?. Cancer 109 (2007) 213-220
2. Kuban D.A., el-Mahdi A.M., and Schellhammer P.F. Prostate-specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer. Int J Radiat Oncol Biol Phys 32 (1995) 307-316
3. Shipley W.U., Thames H.D., Sandler H.M., et al. Radiation therapy for clinically localized prostate cancer: A multi-institutional pooled analysis. JAMA 281 (1999) 1598-1604
4. Zagars G.K., Pollack A., Kavadi V.S., et al. Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 32 (1995) 293-306
5. Kestin L.L., Vicini F.A., Ziaja E.L., et al. Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy. Cancer 86 (1999) 1557-1566
6. Zagars G.K., and von Eschenbach A.C. Prostate-specific antigen. An important marker for prostate cancer treated by external beam radiation therapy. Cancer 72 (1993) 538-548
7. Lee W.R., Hanks G.E., and Hanlon A. Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: Clinical observations. J Clin Oncol 15 (1997) 230-238
8. Thames H., Kuban D., Levy L., et al. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys 57 (2003) 929-943
9. Pollack A., Zagars G.K., and Kavadi V.S. Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer. Cancer 74 (1994) 670-678
10. Sartor C.I., Strawderman M.H., Lin X.H., et al. Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy. Int J Radiat Oncol Biol Phys 38 (1997) 941-947
11. D'Amico A.V., Moul J., Carroll P.R., et al. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol 172 (2004) S42-S46 discussion S46-S47
12. Duchesne G.M., Millar J.L., Moraga V., et al. What to do for prostate cancer patients with a rising PSA? A survey of Australian practice. Int J Radiat Oncol Biol Phys 55 (2003) 986-991
13. American Society for Therapeutic Radiology and Oncology Consensus Panel Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37 (1997) 1035-1041
14. Roach III M., Hanks G., Thames Jr. H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65 (2006) 965-974
15. Thompson I.M., Ankerst D.P., Chi C., et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 294 (2005) 66-70
16. Taylor J.M.G., Yu M., and Sandler H.M. Individualized predictions of disease progression following radiation therapy for prostate cancer. J Clin Oncol 23 (2005) 816-825
17. Michalski J.M., Winter K., Purdy J.A., et al. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V. Int J Radiat Oncol Biol Phys 62 (2005) 706-713
18. Roach M., Winter K., Michalski J.M., et al. Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate cancer on RTOG 9406: Findings from a prospective, multi-institutional, Phase I/II dose-escalation study. Int J Radiat Oncol Biol Phys 60 (2004) 1351-1356
19. Williams S.G., Duchesne G.M., Millar J.L., et al. Both pretreatment prostate-specific antigen level and posttreatment biochemical failure are independent predictors of overall survival after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 60 (2004) 1082-1087
20. Williams S.G., Taylor J.M.G., Liu N., et al. Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer. Int J Radiat Oncol Biol Phys 68 (2007) 24-33
21. Laird N.M., and Ware J.H. Random-effects models for longitudinal data. Biometrics 38 (1982) 963-974
22. Tsiatis A., De Gruttola V., and Wulfsohn M. Modelling the relationship of survival to longitudinal data measured with error. Application to survival and SC4 counts in patients with AIDS. J Am Stat Assoc 90 (1995) 27-37
23. Roach III M., Weinberg V., McLaughlin P.W., et al. Serum prostate-specific antigen and survival after external beam radiotherapy for carcinoma of the prostate. Urology 61 (2003) 730-735
24. Hanlon A.L., Diratzouian H., and Hanks G.E. Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer. Int J Radiat Oncol Biol Phys 53 (2002) 297-303
25. Lee A.K., Levy L.B., Cheung R., et al. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy. Int J Radiat Oncol Biol Phys 63 (2005) 456-462
26. Kwan W., Pickles T., Duncan G., et al. PSA failure and the risk of death in prostate cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys 60 (2004) 1040-1046
27. Zhou P., Chen M.H., McLeod D., et al. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol 23 (2005) 6992-6998
28. Thames H.D., Kuban D.A., DeSilvio M.L., et al. Increasing external beam dose for T1-T2 prostate cancer: Effect on risk groups. Int J Radiat Oncol Biol Phys 65 (2006) 975-981
29. Hanks G.E., Hanlon A.L., Epstein B., et al. Dose response in prostate cancer with 8-12 years' follow-up. Int J Radiat Oncol Biol Phys 54 (2002) 427-435
30. Parker C.C., Gospodarowicz M., and Warde P. Does age influence the behaviour of localized prostate cancer?. Br J Urol Int 87 (2001) 629-637
31. Pickles T. Prostate-specific antigen (PSA) bounce and other fluctuations: Which biochemical relapse definition is least prone to PSA false calls? An analysis of 2030 men treated for prostate cancer with external beam or brachytherapy with or without adjuvant androgen deprivation therapy. Int J Radiat Oncol Biol Phys 64 (2006) 1355-1359